Long-Term Vision –– On the Road to 2030

The NIHON CHOUZAI Group’s Long-Term Vision (announced in April 2018) shows the Group’s vision for the future after having successfully emerged from a reorganization in the industry by using the major changes in the external environment in the medical and pharmaceutical industries as opportunities. We will achieve a dramatic expansion of our Dispensing Pharmacy Business through pharmacy-opening strategies and ICT strategies, then use this as a starting point to expand our Pharmaceutical Manufacturing and Sales Business and Medical Professional Staffing and Placement Business, thereby achieving sustainable growth as a comprehensive healthcare company.

Anticipated external environment

Strategy for rapid expansion

An image of growth leading to 2030

View of business environment changes and corporate growth by 2030

FY2005 (results) FY2018 (results) FY2031 (forecast)
Dispensing Pharmacy Business Net sales 51.8 billion yen 205.2 billion yen 900.0 billion yen
Per-pharmacy annual sales 294 million yen 359 million yen 700 million yen
Number of pharmacies 174 pharmacies 585 pharmacies 1,000 pharmacies
Share of NIHON CHOUZAI generic drug use ― 83.6％ 90～100％
Pharmaceutical Manufacturing and Sales Business Net sales ―※1 38.1 billion yen 300.0 billion yen
Maximum production capacity ― 6.2 billion tablets 15.3 billion tablets
Medical Professional Staffing and Placement Business Net sales 0.7 billion yen 12.0 billion yen 25.0 billion yen
External environment Separation ratio* 2 (outside of hospital prescription ratio) 53.8％ 73.2％ 90～100％※5
Share of generic drug use, volume-based 4.6％※3 72.5％※4 85～95％※5

Figures are rounded off

*1: The NIHON CHOUZAI Pharmaceutical Manufacturing and Sales Business launched in 2005. 
*2: Prepared by NIHON CHOUZAI based on progress of separation of drug prescribing and dispensing (trend of health insurance dispensing) according to the Japan Pharmaceutical Association.
*3: Share of generic drug use, volume-based as of end of FY2006 (previous standard). FY2006 data posted because FY2005 data was not publicly disclosed. 
*4: Share of generic drug use, volume-based as of end of February 2018. 
*5: NIHON CHOUZAI estimates